Truist analyst David MacDonald raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $182 and keeps a Hold rating on the shares on the heels of solid Q1 results featuring in-line revenue, while adjusted EPS and AOI were ahead and the FY25 guide was reaffirmed. Truist views the recent LDT ruling as a nice positive, commentary around tariffs was encouraging, and it expects ongoing AI/automation initiatives to aid efficiency/savings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $194 from $191 at Baird
- Quest Diagnostics: Resilience and Growth Potential Amidst Macroeconomic Challenges
- Quest Diagnostics price target raised to $185 from $175 at Barclays
- Quest Diagnostics Reports Strong Q1 2025 Results
- Quest Diagnostics Reports Strong Growth in Earnings Call